{
  "created_at": "Fri Aug 20 10:24:46 +0000 2021",
  "id_str": "1428661868931989507",
  "full_text": "AstraZeneca will seek regulatory approval for an antibody drug after a study showed strong efficacy in preventing symptomatic Covid-19 https://t.co/e4GFsLc8g5",
  "display_text_range": [
    0,
    158
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/e4GFsLc8g5",
        "expanded_url": "https://on.wsj.com/3zaqO6g",
        "display_url": "on.wsj.com/3zaqO6g",
        "indices": [
          135,
          158
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 33,
  "favorite_count": 92,
  "possibly_sensitive": false,
  "original_created_at": "Fri Aug 20 10:15:07 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "アストラゼネカ社は、症状のあるCovid-19 https://t.co/e4GFsLc8g5 の予防に強い効果があるとの試験結果を受けて、抗体医薬品の承認を目指す。"
    },
    {
      "locale": "zh",
      "full_text": "在一项研究显示对预防有症状的Covid-19有很强的疗效后，阿斯利康将为一种抗体药物寻求监管部门的批准 https://t.co/e4GFsLc8g5"
    },
    {
      "locale": "zh-Hant",
      "full_text": "在一項研究顯示對預防有症狀的Covid-19有很強的療效後，阿斯利康將爲一種抗體藥物尋求監管部門的批准 https://t.co/e4GFsLc8g5"
    }
  ]
}